LSB(Delisted)
LakeShore BiopharmaยทNASDAQ
--
--(--)
Is LSB undervalued or overvalued?
- LSB scores 0.00/10 on fundamentals and holds a Fair valuation at present. Backed by its -18.43% ROE, -16.26% net margin, 0.00 P/E ratio, 0.00 P/B ratio, and 87.19% earnings growth, these metrics solidify its Neutral investment rating.
